GWENDOLYN SHIPE: Open Payments
NPI 1922180322 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,191 in 39 payments from 8 companies in 2025. Trend: 2023 $1,001 · 2024 $719 · 2025 $1,191
Food & beverage: $1,191
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $298 |
| Axsome Therapeutics, Inc. | 7 | $276 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $234 |
| Corcept Therapeutics | 5 | $220 |
| Corium, LLC | 4 | $61 |
| Noven Therapeutics, LLC | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Lilly USA, LLC | 1 | $18 |
Products named: REXULTI, Auvelity, CAPLYTA, Korlym, Azstarys, Xelstrym, FANAPT, ZEPBOUND.
Industry payments across TX — which companies pay providers there.
